HIV and Glucose-6-Phosphate Dehydrogenase (G-6-PD) Deficiency among University Athletes in Rivers State, Nigeria

Main Article Content

I. O. Okonko
S. Adewuyi- Oseni
T. I. Cookey
K. C. Anugweje


Aim: Athletes are not immune to human immunodeficiency virus (HIV) and Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency, and these conditions do not cause any harm or damage to their body as long as the necessary precautions in term of medications and others are adhered to. This research’s main objective was to determine the prevalence rate of G-6-PD deficiency and HIV among the University athletes in Rivers State, Nigeria.

Study Design:  Cross-sectional study.

Place and Duration of Study: Sports Institute, University of Port Harcourt (UNIPORT), Nigeria, between June 2012 and July 2015.

Methods: A total of 258 athletes were screened (134 females and 124 males) for HIV and G-6-PD deficiency. The athletes’ ages, gender and dates of birth were obtained and recorded. The presence of the HIV-1 and HIV-2 antibody was detected using the Uni-Gold™ Recombigen® HIV-1/2 for the detection of HIV. While Beutler Semi-quantitative G-6-PD Test Kit (BSA-3000) was utilized for the quantitative detection of G-6-PD deficiency in whole blood.

Results: Of the 258 athletes tested, 0.7% was G-6-PD deficient while 1.2% was positive for HIV. The G-6-PD deficient positive cases were found in the age range of 21-25 years while the higher prevalence of HIV was observed in the age range 31-35 years (4.8%), followed by 26-30 years (1.9%) and the least was observed in the age group 21-25 years (0.7%). Age and gender had no significant relationship with the positivity of the athletes to HIV and G-6-PD (p-value >0.05).

Conclusion: This study confirms the presence of HIV and G-6-PD deficiency among university athletes in Rivers State, Nigeria. This calls for routine testing of both the athletes and the general public for G-6-PD deficiency to prevent hemolysis causes by G-6-PD deficiency.

Athletes, HIV, G-6-PD deficiency, Uni-Gold, Nigeria

Article Details

How to Cite
Okonko, I. O., Oseni, S. A.-, Cookey, T. I., & Anugweje, K. C. (2020). HIV and Glucose-6-Phosphate Dehydrogenase (G-6-PD) Deficiency among University Athletes in Rivers State, Nigeria. Asian Journal of Biochemistry, Genetics and Molecular Biology, 4(4), 36-41.
Original Research Article


Prchal JT, Gregg XT. Red cell enzymes. Hematology. American Society of Hematology. Education Program. 2005; 19–23.

Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Practice and Research: Clinical Haematology. 2000;13:21-38.

Steiner LA, Gallagher PG. Erythrocyte disorders in the perinatal period. Seminars in Perinatology. 2007;4:254- 261.

Frank JE. Diagnosis and management of G-6-PD deficiency. American Family Physician. 2005;72(7):1277-1282.

Chen EY, Cheng A, Lee A, Kuang WJ, Hillier L, Green P, Schlessinger D, Ciccodicola A, D'Urso M. Sequence of human glucose-6-phosphate dehydro-genase cloned in plasmids and a yeast artificial chromosome. Genomics. 1991; 10(3):792-800.

Beutler E, Vulliamy TJ. Hematologically important mutations: Glucose-6-phosphate dehydrogenase. Blood Cells, Molecules & Diseases. 2002;28(2):93–103.

Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bulletin of the World Health Organization. 1989; 67(6):601–611.

Luzzatto L, Mehta A, Vulliamy TJ. (Glucose 6-phosphate dehydrogenase deficiency. In The Metabolic and Molecular Bases of Inherited Disease, 8th edition (Scriver CR, Beaudet AL, Sly WS, Valle D, Eds.), McGraw-Hill, New York. 2000;4517–4553.

Cappellini MD, Fiorelli G. Glucose-6-Phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74.

Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. Blood Cells, Molecules, and Diseases. 2009;42(3):267–278.

Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla, CD, Baird JK, Hay SI. G-6-PD deficiency prevalence and estimates of affected populations in malaria-endemic countries: A geostatistical model-based map. PLoS Medicine. 2012;9(11): e1001339.

Clem KL, Borchers JR. HIV and the athlete. Clinics in Sports Medicine. 2007; 26:413-424.

Shah SS, Diakite SAS, Traore K, Diakite M, Kwiatkowski DP, Rockett KA. A novel cytofluoro-metric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Scientific Report. 2012;2:29-30.

NACA. End of Term Desk Review Report of the 2010-2015 National HIV/AIDS Strategic Plan; 2015.

UNAIDS. Global facts sheet: AIDSinfo; 2019.


[Accessed 22/07/2020]

Akanni EO, Oseni BSA, Agbona VO, Tijani BA, Tosan E, Fakunle EE, Mabayoje VO. Glucose-6-phosphate dehydrogenase deficiency in blood donors and jaundiced neonates in Osogbo, Nigeria. Journal of Medical Laboratory and Diagnosis. 2010; 1(1):1-4.

Jidda M, Ibrahim K, Aiki G, Ngaski AA, Blessing J, Asiya U, Nwachukwu C. The Prevalence of Glucose-6-Phosphate Dehydrogenase (G-6-PD) Deficiency in Students of Sultan Abdurrahaman School of Health Technology Gwadabawa, Sokoto, North-Western Nigeria. International Blood Research & Reviews. 2017;7:1-6.

DOI: 10.9734/IBRR/2017/31901

Ademowo OG, Falusi AG. Molecular epidemiology and activity of erythrocyte G-6-PD variants in a homogeneous Nigerian population. East African Medical Journal. 2002;79(1):42–45.

Luzzatto L. Glucose-6-phosphate dehydrogenase deficiency: From genotype to phenotype. Haematologica. 2006;91: 1303-1306.

Beutler E. Glucose-6-phosphate dehydrogenase deficiency: A historical perspective. Blood. 2008;111(1):16–24.

Serpa JA, Villarreal-Williams E, Giordano TP. Prevalence of G-6-PD deficiency in a large cohort of HIV-infected patients. Journal of Infection. 2010;61: 399–402.

Xu JZ, Francis RO, Lerebours Nadal LE, Shirazi M, Jobanputra V, Hod EA, Jhang JS, Stotler BA, Spitalnik SL, Nicholas SW. G-6-PD deficiency in an HIV clinic setting in the Dominican Republic. American Journal of Tropical Medicine and Hygiene. 2015;93:722– 729.

Tungsiripat M, Drechsler H, Sarlone C, Amyot K, Laffey E, Aberg J. Prevalence and significance of G-6-PD deficiency in patients of an urban HIV clinic. Journal of the International Association of Physicians in AIDS Care. 2008;7:88–90.

Rapezz D, Porqueddu EM, Fenu L, Racchi O, Ferraris AM, Gaetani GF, Aceti A. Survival of people who are HIV-1-positive and G-6-PD-deficient is unaffected by virus-induced oxidative stress. Lancet. 1998;351:264–265.

Ciccolo JT, Jowers EM, Bartholomew JB. The benefits of exercise for quality of life in the post HAART era. Sports Medicine. 2004;34(8):487–99.

Burnham TR, Wilcox A. Effects of exercise on physiological and psychological variables in cancer survivors. Medicine and Science in Sports and Exercise. 2002; 34(12):1863–1867.

Stone SN, Reisig KV, Saffel HL, Miles CM. Management of athletes with G-6-PD deficiency: Does missing an enzyme mean missing more games? Sports Health. 2020;12(2):149–153.